| Literature DB >> 32392257 |
Amber Nous1, Ilse Peeters1, Koenraad Nieboer2, Anne-Marie Vanbinst2, Jacques De Keyser1, Sylvie De Raedt1.
Abstract
BACKGROUND: Spleen volume reduction followed by re-expansion has been described in acute ischemic stroke in both animal and human studies. Splenic contraction might be partially due to sympathetic hyperactivity and might be accompanied by release of splenocytes in the peripheral circulation, leading to immunodepression. AIMS: To investigate whether spleen volume changes in the first week after stroke are associated with post-stroke infections, changes in lymphocytes count and autonomic dysfunction.Entities:
Year: 2020 PMID: 32392257 PMCID: PMC7213723 DOI: 10.1371/journal.pone.0232497
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Main characteristics of patients with and without spleen volume reduction.
| Spleen Volume Reduction (n = 11) | No Spleen Volume Reduction (n = 27) | P-value | |
|---|---|---|---|
| Female Sex | 4 [36%] | 9 [33%] | 1 |
| Age, yrs | 70 [IQR 59;85] | 77 [IQR 65;82] | 0,974 |
| Stroke Volume, cm3 | 4 [IQR 3;42] | 3 [IQR 1;14] | 0,161 |
| Thrombolysis | 9 [81%] | 17 [63%] | 0,444 |
| NIHSS–admission | 11 [IQR 6;17] | 7 [IQR 5;9] | |
| NIHSS—day 1 | 10 [IQR 4;15] | 5 [IQR 2;6] | 0,075 |
| NIHSS—day 3 | 10 [IQR 4;17] | 2 [IQR 1;5] | |
| Early neurological deterioration | 2 [18%] | 0 [0%] | 0,078 |
| Poor neurological outcome | 8 [73%] | 9 [33%] | 0,141 |
| Mortality | 3 [27%] | 2 [7%] | 0,300 |
| Post-stroke infection | 6 [55%] | 5 [19%] | |
| SDNNrr | 21 [IQR 19;25] | 26 [IQR 14;37] | 0,809 |
| RMSSD | 20 [IQR 14;32] | 25 [IQR 15;31] | 0,717 |
| HFms2 | 134 [IQR 27;246] | 149 [IQR 48;580] | 0,468 |
| HF% | 34 [IQR 26;39] | 40 [IQR 24;44] | 0,545 |
| LFms2 | 39 [IQR 24;78] | 129 [IQR 31;302] | 0,304 |
| LF% | 16 [IQR 9;50] | 32 [IQR 20;50] | 0,431 |
| LF/HF | 0,7 [IQR 0,3;1,8] | 1 [IQR 0,63;1,24] | 0,628 |
| Prior to stroke | 2 [18%] | 10 [37%] | 0,444 |
| During hospitalisation | 3 [27%] | 9 [33%] | 1,000 |
Data are expressed as median +/- IQR [Q1,Q3] or number as appropriate. P-values were calculated with the Fisher Exact test and Mann-Whitney U test. Poor neurological outcome data were missing in 4 patients, PRV parameters in 13 patients due to atrial fibrillation, pacemaker, technical problems with the Nexfin monitor.
Abbreviations: NIHSS = National Institutes of Health Stroke Scale, PRV = pulse rate variability, SDNN = standard deviations of all NN-intervals, RMSSD = the square root of the mean of the sums of the squares of differences between adjacent NN intervals, LF = low frequency power, HF = high frequency power, ms2 = absolute power; % = relative power = absolute power (ms2)/total power (ms2)*100%.
Fig 1Time course of lymphocytes, monocytes and neutrophils in patients with and without spleen volume reduction, displayed as median with IQR.
Patients with spleen volume reduction are shown in black, patients without in grey. In the group without spleen volume reduction, a complete dataset regarding lymphocytes, monocytes and neutrophils was missing in 8 patients. #Indicates significant difference between two different days within the same group.
Fig 2Lymphocyte and lymphocyte subset numbers on admission and day one in patients with versus without spleen volume reduction, displayed as median with IQR.
Patients with spleen volume reduction are shown in black, patients without in grey. Regarding lymphocytes, 3 datasets were missing in the group without spleen volume reduction. Regarding lymphocyte subsets, 6 complete datasets were missing in the group without spleen volume reduction, 1 in the group with spleen volume reduction. # Indicates significant difference between two different days within the same group. *Indicates significant difference between both groups on the same day.